Bristol Pravachol Promotion Cited For Misleading Superiority Claim By FDA
Executive Summary
Bristol-Myers Squibb's Pravachol (pravastatin) physician-directed promotions contain unsubstantiated superiority safety claims over other cholesterol-lowering drugs, FDA's ad division maintains.